References
-
1
Groop L C.
Sulphonylureas in NIDDM.
Diabetes Care.
1992;
15
737-754
-
2
Ligtenberg J JM, Sluiter W J, Reitsma W D, van Haeften T W.
Effect of glibenclamide on insulin release at moderate and high hyperglycemia in man.
Eur J Clin Invest.
1997;
27
685-689
-
3
van der Wal P S, Heine R J.
Characteristics of pancreatic beta-cell secretion in type 2 diabetic patients treated with gliclazide and glibenclamide.
Diabetes Res Clin Pract.
2001;
52
103-111
-
4
Delia Casa L, Del Rio G, Glaser B, Cerasi E.
Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: Role of initial continuous subcutaneous insulin infusion-induced normoglycemia.
Am J Med.
1990;
90
37S-45S
Dr. T. W. van Haeften
Department of Internal Medicine G 02.228 · University Medical Center
PO Box 85500 · 3508 GA Utrecht · The Netherlands
Telefon: + 31 (30) 250 62 56
Fax: + 31 (30) 251 83 28
eMail: t.w.vanhaeften@azu.nl
